26 August 2015
Sanofi and Regeneron have announced that the US Food and Drug Administration (FDA) has approved Praluent® (alirocumab) Injection.
Praluent is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein (LDL) cholesterol. The effect of Praluent on cardiovascular morbidity and mortality has not been determined.
////////Sanofi, Regeneron, US Food and Drug Administration, FDA, approved, Praluent® , alirocumab
Filed under: FDA 2015 Tagged: alirocumab, Approved, fda, FDA 2015, Praluent®, regeneron, SANOFI, US Food and Drug Administration
